Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 49,270 shares, an increase of 78.9% from the November 30th total of 27,540 shares. Based on an average daily trading volume, of 146,092 shares, the days-to-cover ratio is currently 0.3 days. Approximately 2.7% of the company’s stock are sold short. Approximately 2.7% of the company’s stock are sold short. Based on an average daily trading volume, of 146,092 shares, the days-to-cover ratio is currently 0.3 days.

Analysts Set New Price Targets

BJDX has been the topic of several analyst reports. Wall Street Zen raised shares of Bluejay Diagnostics to a “sell” rating in a report on Saturday, November 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Bluejay Diagnostics currently has an average rating of “Sell”.

Bluejay Diagnostics Trading Down 0.9%

BJDX stock opened at $0.70 on Friday. The stock has a market cap of $1.27 million, a P/E ratio of -0.01 and a beta of 0.61. Bluejay Diagnostics has a twelve month low of $0.65 and a twelve month high of $10.20. The company’s 50 day moving average is $1.47 and its two-hundred day moving average is $1.59.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Friday, November 7th. The company reported ($1.01) earnings per share (EPS) for the quarter.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.